Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

Inhibikase Therapeutics, Inc. is a pharmaceutical company focused on the development of protein kinase inhibitors for treatment of neurological infections and neurodegenerative diseases. The Company’s pipeline includes multiple product candidates developed from its proprietary RAMP drug innovation and prodrug technology engines, using the same clinically validated kinase target. The Company is headquartered in Atlanta with additional offices in Boston, Massachusetts.

Stock Snapshot

IR Contacts


Inhibikase Therapeutics, Inc.
3350 Riverwood Parkway
Suite 1900
Atlanta, GA 30339
T: 678-392-3419

Investor Relations

Alex Lobo
T: 212-698-8802

Transfer Agent

American Stock Transfer & Trust Company, LLC
T: 800-937-5449